Sponsor:
AstraZeneca
Code:
NCT07611110
Conditions
Metastatic Castration-resistant Prostate Cancer
Eligibility Criteria
Sex: Male
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265])
Cabazitaxel
Abiraterone
Enzalutamide
Apalutamide
Brief summary:
Conditions
Metastatic Castration-resistant Prostate Cancer
Study ID
NCT07611110
Start date
May 4, 2026
Status verified date
Oct, 2026
Completion date
Jun 6, 2030
Anticipated
Primary completion date
Jun 4, 2029
Anticipated
Eligibility Criteria
Sex: Male
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
670 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Treatment
Arms
experimental: Arm A
active comparator: Arm B
Interventions
Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265])
Cabazitaxel
Abiraterone
Enzalutamide
Apalutamide
Darolutamide
Deutenzalutamide
Radium-223
Primary outcome measure
Central contacts
Locations
Research Site
Recruiting
Dothan, Alabama, United States, 36303
Research Site
Recruiting
Duarte, California, United States, 91010
Research Site
Recruiting
Newport Beach, California, United States, 92660
Research Site
Recruiting
San Francisco, California, United States, 94143
Research Site
Recruiting
Miami, Florida, United States, 33165
Research Site
Recruiting
Metairie, Louisiana, United States, 70006
Research Site
Recruiting
Omaha, Nebraska, United States, 68130
Research Site
Recruiting
New York, New York, United States, 10065
Research Site
Recruiting
Pittsburgh, Pennsylvania, United States, 15232
Research Site
Recruiting
Myrtle Beach, South Carolina, United States, 29572
Research Site
Recruiting
Nashville, Tennessee, United States, 37203
Research Site
Recruiting
Houston, Texas, United States, 77042
Research Site
Recruiting
Toronto, Ontario, Canada, M4N 3M5
Research Site
Recruiting
Montreal, Quebec, Canada, H3A 1A1
Research Site
Recruiting
Montreal, Quebec, Canada, H3T 1E2
Sponsor
AstraZeneca
Last update posted
Oct 19, 2026
Last verified
Oct, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-17. This information was provided to ClinicalTrials.gov by AstraZeneca on 2026-10-19. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.